Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07105111 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
A Phase 4 study of Schizophrenia and Major Depressive Disorder, sponsored by Neurocrine Biosciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 8
- Study locations
NCT07105111: Recruiting Phase 4 study of Schizophrenia and Major Depressive Disorder, sponsored by Neurocrine Biosciences.
NCT07105111 is a Phase 4 study of Schizophrenia and Major Depressive Disorder that is actively recruiting participants, run by Neurocrine Biosciences. The registered enrollment target is 50 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% lower). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07105111, a Phase 4 study of Schizophrenia and Major Depressive Disorder, is actively recruiting participants, sponsored by Neurocrine Biosciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
Conditions Studied
Interventions
- DRUG Valbenazine
Study Locations (8)
Florida
- Neurocrine Clinical Site - Bonita Springs
- Neurocrine Clinical Site - Hialeah
- Neurocrine Clinical Site - Miami
- Neurocrine Clinical Site - Tampa
California
- Neurocrine Clinical Site - Fountain Valley
- Neurocrine Clinical Site - Orange
Arkansas
- Neurocrine Clinical Site - Bryant
Georgia
- Neurocrine Clinical Site - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-08-29 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
What NCT07105111 shows while recruiting
NCT07105111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% lower).
The record links to 5 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Valbenazine is the first listed.
NCT07105111 lists 8 locations in 4 states (Florida, California, Arkansas).
Frequently Asked Questions
What is clinical trial NCT07105111 about?
NCT07105111 is a clinical study titled "A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor". This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
What is the current status of trial NCT07105111?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2025-08-29. Estimated completion is 2027-04.
What conditions does trial NCT07105111 study?
This clinical trial studies the following conditions: Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder, Tardive Dyskinesia.
What interventions are being tested in trial NCT07105111?
The interventions under investigation include: Valbenazine (DRUG).
Who is sponsoring clinical trial NCT07105111?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07105111 being conducted?
This trial has 8 study locations across Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07105111's enrollment target sits among peer trials
50 208th of 315 higher than 101 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
-
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI